Drug Trial Radar · NCT07374471
A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
Jul 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Mage BiologicsIndustry
- Sponsor type
- Industry
- First posted
- Jan 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if MB-001, an oral biologic, is able to treat patients with ulcerative colitis. Participants will be asked to take MB-001 or a matching placebo once-daily for a period of 12 weeks. Researchers will compare MB-001 to placebo to investigate its effects on clinical symptoms as well as endoscopic and histopathological findings. Patients will be offered open-label extension for another 12 weeks following the double-blind, placebo-controlled part of the study. Participants will keep a daily diary to record their symptoms and will have up to nine clinic visits.
Conditions
- Ulcerative Colitis (UC)
Interventions
MB-001Biological
oral capsule formulation
Matching placebo to MB-001Biological
oral capsule formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: From study start until 4 weeks after end of treatment
- Changes in laboratory parameters: Platelet countTime frame: Week 12
- Changes in laboratory parameter: HemoglobinTime frame: Week 12
- Changes in laboratory parameter: HematocritTime frame: Week 12
- Changes in laboratory parameter: Red Blood Cell (RBC) countTime frame: Week 12
- Changes in laboratory parameter: Prothrombin timeTime frame: Week 12
- Number of participants with abnormal laboratory tests resultsTime frame: Week 12
- Number of participants with abnormal urinalysis resultsTime frame: Week 12
- Proportion of participants achieving clinical remissionTime frame: Week 12
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
2001
Tbilisi, Georgia · Recruiting
3001
Chisinau, Moldova · Recruiting
4002
Katowice, Poland · Recruiting
4001
Warsaw, Poland · Recruiting
4003
Wroclaw, Poland · Recruiting
1003
Ivano-Frankivsk, Ukraine · Recruiting
1001
Kyiv, Ukraine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.